Table 2.
Immune response to vaccination in the VELOCE study.
Response rates were measured 8 weeks following vaccination with tetanus toxoid and 4 weeks following vaccination with pneumovax, or influenza.
| Immune response to vaccination in the VELOCE study | ||
|---|---|---|
| Vaccine | Immune response in Ocrelizumab treated | Immune response in control |
| tetanus toxoid | positive response rate: 23.9% | positive response rate: 54.5% |
| Pneumovax (23-PPV) | positive response rate to ≥5 serotypes: 71.6% | positive response rate to ≥5 serotypes: 100% |
| 2015/2016 or 2016/2017 Northern Hemisphere seasonal influenza | Seroprotection rates to all 5 strains: 55.6%-80.0% | Seroprotection rates to all 5 strains: 75.0%-97.0% |